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DOI 10.1186/s13075-015-0690-6RESEARCH ARTICLE Open AccessRheumatoid arthritis–associated
autoantibodies in non–rheumatoid arthritis
patients with mucosal inflammation: a
case–control study
Koen M J Janssen1†, Menke J de Smit2†, Elisabeth Brouwer3, Fenne A C de Kok3, Jan Kraan4, Josje Altenburg5,
Marije K Verheul6, Leendert A Trouw6, Arie Jan van Winkelhoff2,7, Arjan Vissink1 and Johanna Westra3*Abstract
Introduction: Rheumatoid arthritis–associated autoantibodies (RA-AAB) can be present in serum years before
clinical onset of rheumatoid arthritis (RA). It has been hypothesized that initiation of RA-AAB generation occurs at
inflamed mucosal surfaces, such as in the oral cavity or lungs. The aim of this study was to assess systemic presence
of RA-AAB in patients without RA who had oral or lung mucosal inflammation.
Methods: The presence of RA-AAB (immunoglobulin A [IgA] and IgG anti-cyclic citrullinated peptide 2 antibodies
(anti-CCP2), IgM and IgA rheumatoid factor (RF), IgG anti-carbamylated protein antibodies and IgG and IgA
anti-citrullinated peptide antibodies against fibrinogen, vimentin and enolase) were determined in sera of non-RA
patients with periodontitis (PD, n = 114), bronchiectasis (BR, n = 80) or cystic fibrosis (CF, n = 41). Serum RA-AAB
levels were compared with those of periodontally healthy controls (n = 36). Patients with established RA (n = 86)
served as a reference group. Association of the diseases with RA-AAB seropositivity was assessed with a logistic
regression model, adjusted for age, sex and smoking.
Results: Logistic regression analysis revealed that IgG anti-CCP seropositivity was associated with BR and RA,
whereas the association with PD was borderline significant. IgA anti-CCP seropositivity was associated with CF and
RA. IgM RF seropositivity was associated with RA, whereas the association with BR was borderline significant. IgA RF
seropositivity was associated with CF and RA. Apart from an influence of smoking on IgA RF in patients with RA,
there was no influence of age, sex or smoking on the association of RA-AAB seropositivity with the diseases.
Anti-CarP levels were increased only in patients with RA. The same held for IgG reactivity against all investigated
citrullinated peptides.
Conclusion: Although overall levels were low, RA-AAB seropositivity was associated with lung mucosal inflammation
(BR and CF) and may be associated with oral mucosal inflammation (PD). To further determine whether mucosal
inflammation functions as a site for induction of RA-AAB and precedes RA, longitudinal studies are necessary in which
RA-AAB of specifically the IgA isotype should be assessed in inflamed mucosal tissues and/or in their inflammatory
exudates.* Correspondence: johanna.westra@umcg.nl
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The first autoantibody discovered in rheumatoid arthritis
(RA) was rheumatoid factor (RF), which is directed
against the constant domain of the immunoglobulin G
(IgG) molecule. RF is not very specific for RA, as it is
commonly found in other (autoimmune) diseases, too
[1–4]. In contrast to RF, anti-citrullinated protein anti-
bodies (ACPA) are highly specific (98 %) for RA [5].
ACPA can be directed against a number of citrullinated
autoantigens. Production of ACPA in RA is associated
with distinct genetic risk factors [6] and worse disease
outcome [7].
Recently, anti-carbamylated protein antibodies (anti-
CarP) were described as a third autoantibody system in
RA [8]. Carbamylation is, like citrullination, a post-
translational modification and results in a chemically
similar structure [9]. Antibodies, however, are able to
distinguish between carbamylated and citrullinated anti-
gens. As for RF and ACPA [10, 11], the presence of anti-
CarP in serum can precede clinical onset of RA and is
associated independently of ACPA with a higher risk of
developing RA [12].
Although the presence of ACPA and RF is of great im-
portance in RA diagnosis, the role of these antibodies in
the initiation and pathogenesis of RA has been less well
elucidated. It has been hypothesized that initiation of
RA-associated autoantibody (RA-AAB) generation oc-
curs at inflamed mucosal surfaces, such as in the lung
and oral mucosa [13]. IgA is the predominant antibody
of the mucosal immune system, and IgA ACPA is ele-
vated and highly specific for RA in individuals with pre-
clinical and early RA [14–16].
Because smoking is a risk factor for RA development
[17], the lungs have been speculated to play a role in RA
initiation [18]. Smoking induces chronic inflammation at
mucosal surfaces [19] and act as an environmental trigger
for the appearance of specifically IgA ACPA before onset
of RA [15]. Lung mucosal inflammation (e.g., bronchiec-
tasis [BR]) is more commonly found in patients with RA
than in the general population [20]. The capability of
plasma cells in inducible bronchus-associated lymphoid
tissue to produce ACPA and RF [21], as well as the in-
creased presence of airway abnormalities in arthritis-free
individuals with serum RF and/or ACPA positivity as com-
pared with ACPA- and RF-negative controls [22], may in-
dicate a role for the respiratory system in the initiation of
RA-AAB.
The association between RA and BR suggests that RA
may occur at an increased rate in patients with cystic fi-
brosis (CF). The prevalence of rheumatic symptoms in-
creases with age and CF severity and is associated with
lung superinfection. However, an association with defin-
ite RA is not yet established [23]. After years of antigen
stimulation, episodic arthritis could progress to RA [24].Mutations in the cystic fibrosis transmembrane conduct-
ance regulator (CFTR) gene may play a role in this pro-
gression [25]. Compared with healthy controls (HC), RF
is increased in patients with CF, specifically in patients
with CF who have episodic arthritis [24]. Up to now,
there are no data on the presence of other RA-AAB in
patients with CF.
As well as being a risk factor for RA, smoking is a risk
factor for mucosal inflammation in the periodontal re-
gion (periodontitis [PD]) [26]. Microorganisms orga-
nized in the subgingival biofilm are the primary etiologic
agents in PD. The periodontal pathogen Porphyromonas
gingivalis has been hypothesized to be involved in ACPA
initiation owing to its own peptidyl arginine deiminase
(PAD) enzyme necessary for protein citrullination [27, 28].
P. gingivalis peptidyl arginine deiminase (PPAD) is able to
citrullinate endogenous and human proteins, thereby cre-
ating antigens that have been presumed to initiate the
ACPA response in RA [29]. Recently, this hypothesis has
been expanded by myeloperoxidase-mediated protein car-
bamylation and associated anti-CarP production in the in-
flamed oral mucosa of patients with PD [30]. Therefore,
PD has been posed as a candidate risk factor for RA [31].
Reactivity against native forms of citrullinated RA
autoantigens was found in sera from patients with RA
before clinical symptoms occurred [32]. Recently, re-
activity against native forms of citrullinated RA autoanti-
gens in PD patients with PD was found to be increased
compared with non-PD controls [33]. These findings
have raised the hypothesis that, at least in some individ-
uals, reactivity against citrullinated autoantigens is pre-
ceded by reactivity against their native forms [33].
The aim of this study was to assess inflammation of the
oral and lung mucosa as a potential cause of RA-AAB
production. RA-AAB were assessed in sera of patients
without RA with PD, BR or CF. In addition, reactivity
against the native forms of citrullinated autoantigens was
assessed. RA-AAB serum levels were analyzed within the
context of HC and patients with established RA.
Methods
Patient groups
Serum autoantibody levels were measured in adult pa-
tients without RA with PD) (n = 114), non-CF patients
with BR (n = 80) and patients with CF (n = 41). Subjects
without systemic disease and without PD served as the
HC group (n = 36). Patients with established RA without
lung disease and with known periodontal status served
as a reference group (RA group, n = 86).
Patients with untreated severe PD were recruited from a
referral practice for periodontology (Clinic for Periodon-
tology Groningen). The inclusion criterion was >30 % of
sites involved with clinical attachment loss ≥5 mm on the
basis of full-mouth oral measurements [34]. The exclusion
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and having systemic disease other than PD. To assess
the inflammatory burden exerted by the periodontium,
the periodontal inflamed surface area (PISA) [35] was
quantified.
Sera from patients with BR without CF and without RA
from a previously conducted randomized controlled trial
were included [36]. Baseline serum samples were used to
avoid a possible influence of treatment on antibody levels.
Sera from a cohort of patients with CF without RA who
visited the Department of Pulmonology of the University
Medical Center Groningen for routine checkups were in-
cluded. For BR and CF patients, the number of exacerba-
tions was based on the number of antibiotic courses
received 12 months before inclusion. The percentage pre-
dicted forced expiratory volume in 1 second (%FEV1) at
inclusion was used as a disease activity measure.
HC subjects were recruited from among subjects planned
for first consultation at the dental department of the
University Medical Center Groningen. Periodontal health
was assessed using the Dutch periodontal screening index
(DPSI) [37]. An inclusion criterion was DPSI score ≤2 (ab-
sence of PD), and exclusion criteria were antibiotic use <3
months before inclusion and presence of systemic disease.
Patients with established RA without lung disease at
the time of inclusion and with known periodontal status
as assessed by the DPSI served as a reference group for
serological measurements. RA disease activity was
assessed using the Disease Activity Score 28 tender and
swollen joint count (DAS28).
In PD, RA and HC subgingival microbiological sam-
ples were tested for presence of P. gingivalis by using an-
aerobic culture techniques (for details, see [38]).
Participants provided written informed consent before
study enrollment according to the Declaration of
Helsinki. This study was conducted with the approval of
the Medical Ethical Committee of the University Med-
ical Center Groningen (METC UMCG 2009/356, METC
UMCG 2011/010) and Medical Ethical Committee
Noord-Holland (METC Noord-Holland M07-002).
Laboratory measurements
IgG anti-cyclic citrullinated protein antibody (anti-CCP)
levels were measured using a commercial anti-CCP2 kit
(Euro Diagnostica, Malmö, Sweden) according to the
manufacturer’s protocol. Samples with a value <25 U/ml
were measured again with an adjusted protocol in which
samples were diluted 1:10 instead of 1:50. The diagnos-
tic cutoff value was defined as >25 U/ml according to
the manufacturer’s instruction. However, IgG anti-CCP
was not used as a diagnostic test for RA in this study;
therefore, seropositivity was defined as >2 SD above the
mean of HC (2.2 U/ml), analogous to the other auto-
antibodies measured.IgA anti-CCP measurements were performed using a
modification of the anti-CCP2 kit (Euro Diagnostica).
Sera were diluted 1:50 using the dilution buffer provided
by the manufacturer. The secondary antibody was horse-
radish peroxidase (HRP)-conjugated polyclonal goat
anti-human IgA (SouthernBiotech, Birmingham, AL,
USA), diluted 1:20,000 in phosphate-buffered saline
(PBS) with 1 % bovine serum albumin (BSA) and 0.05 %
Tween-20 (Sigma-Aldrich, St. Louis, MO, USA). The
color reaction was performed using tetramethylbenzi-
dine (Sigma-Aldrich) and hydrogen peroxide. A pool of
four sera from RA patients with high levels of IgA anti-
CCP served as a calibrator for the standard curve expressed
in arbitrary units per milliliter (AU/ml) and starting at 200
AU/ml. Seropositivity was defined as >2 SD above the
mean of HC.
To assess the citrulline-specific nature of the response,
sera were tested on plates coated with the arginine-
containing counterpart of CCP2: cyclic arginine peptide
(CAP, kindly provided by Euro Diagnostica), following
almost the same protocol as described for the IgG and
IgA CCP2 enzyme-linked immunosorbent assay (ELISA).
A dilution of patient serum with high levels of IgG anti-
CAP served as a calibrator for the standard curve, starting
at 100 AU/ml. Similarly, IgA anti-CAP reactivity was mea-
sured with a dilution of a high-level responding serum
serving as a standard curve, starting at 100 AU/ml. Sero-
positivity was defined as >2 SD above the mean of HC.
Levels of IgG anti-CarP antibodies against carbamy-
lated fetal calf serum were assessed using a protocol de-
scribed by Shi et al. [8]. Seropositivity was defined as >2
SD above the mean of a distinctive HC cohort [8].
The specificity of the response against citrullinated pro-
teins was assessed by testing reactivity against four syn-
thetic citrullinated peptides that are known autoantigens in
RA: fibrinogen-1 (Fib1, β-chain amino acids 36–52,
NEEGFFSACitGHRPLDKK), fibrinogen-2 (Fib2, β-chain
amino acids 60–74, CitPAPPPISGGGYCitACit), α-enolase
(CEP-1, KIHACitEIFDSCitGNPTVE) and vimentin (Vim1,
VYATCitSSAVCitLCitSSV). Every peptide was linked with
its N terminus to biotin with a spacer (SGSG) in between.
Reactivity against the citrullinated and native forms of the
peptides was measured according to the method of van de
Stadt et al. [39] with some modifications. In short, 96-well
Costar plates (Corning, Corning, NY, USA) were coated
overnight with 5 μg/ml streptavidin (Rockland Immuno-
chemicals, Limerick, PA, USA) in PBS. Subsequently,
plates were blocked for at least 1 hour with 2 % BSA and
0.05 % Tween-20 in PBS followed by incubation with the
biotin-labeled peptides (0.5 μg/ml in PBS). Next, serum
samples were diluted 1:100 in high-performance ELISA
buffer (Sanquin, Amsterdam, the Netherlands) and incu-
bated on the plates. Reactivity was detected with HRP-
conjugated monoclonal mouse anti-human IgG (clone
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BSA and 0.05 % Tween-20 or with HRP-conjugated poly-
clonal goat anti-human IgA (SouthernBiotech) diluted
1:4000 in the same dilution buffer. Bound antibodies were
visualized by using tetramethylbenzidine and hydrogen
peroxide. Reactivity against a citrullinated peptide and its
native counterpart was measured on the same plate. Every
serum sample was measured in duplicate, and a positive
control serum sample was applied on each plate. The
citrulline-specific response was expressed as the difference
in optical density (ΔOD) between the citrullinated peptide
and its native form, and it was considered positive when
ΔOD was >2 SD above the mean of HC. Likewise, the
arginine-specific response was expressed as ΔOD between
the native peptide and its citrullinated form, and it was
considered positive when ΔOD was >2 SD above the mean
of HC.
IgM and IgA RF levels were assessed using a validated
in-house ELISA [40]. Levels were expressed in inter-
national units (IU) per milliliter, and seropositivity was
defined as >10 IU/ml for IgM RF and >25 IU/ml for IgA
RF [40].
C-reactive protein levels were measured by performing
ELISA (DuoSet; R&D Systems, Minneapolis, MN, USA).
Absorbance was read at 450 nm in an EMax micro-
plate reader, and antibody levels were calculated by
using SoftMax PRO software (Molecular Devices,
Sunnyvale, CA, USA).Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (version 5.00 for Windows; GraphPad Software,
La Jolla, CA, USA) and IBM SPSS Statistics for
Windows software (version 20.0; IBM, Armonk, NY,
USA). Normality was tested using D’Agostino-Pearson
omnibus K2 test. For group comparisons, a Mann–
Whitney U test was used for continuous variables and
Fisher’s exact test for categorical variables. Comparison
of RA-AAB levels between the groups was done with
Kruskal–Wallis one-way analysis of variance with Dunn’s
multiple-comparisons post-test compared with HC if
overall p < 0.05. A logistic regression model was used to
analyze the association of the diseases with seropositivity
for anti-CCP and RF. The model was adjusted for age,
sex and smoking (former and current versus never). A
logistic regression model appeared to be better than a
linear regression model owing to non-normally distrib-
uted residuals. Associations of anti-CCP, RF and anti-
CarP with disease activity were assessed by using a
Mann–Whitney U test or an unpaired t-test with or
without Welch’s correction, depending on normality and
equality of variances. Correlations between different pa-
rameters were assessed by Spearman’s ρ.Results
The vast majority of all patient groups was Caucasian.
The demographic and clinical characteristics of patient
groups are listed in Table 1. Age varied significantly be-
tween the groups, being related to the specific ages at
which a certain disease is mostly present; for example,
patients with CF are of young age owing to the low sur-
vival rate of the disease.
Anti-CCP and anti-CAP levels
Compared with HC, IgG and IgA anti-CCP levels were
increased in patients with CF (both p < 0.01) and pa-
tients with RA (both p < 0.0001). IgG anti-CCP sero-
positivity was 13 %, 21 %, 24 % and 86 % in PD, BR, CF
and RA patients, respectively, and 5.6 % in HC. Accord-
ing to the diagnostic cutoff, IgG anti-CCP seropositivity
was 0.9 %, 3.8 %, 2.4 % and 76 % in PD, BR, CF and RA,
respectively, and absent in HC. Seropositivity for IgA
anti-CCP was 16 %, 10 %, 27 % and 74 % in PD, BR, CF
and RA patients, respectively, and 8.3 % in HC (Fig. 1).
Reactivity against the native counterpart of CCP (anti-
CAP) was, compared with HC, increased in RA patients
for IgG anti-CAP (p < 0.01) and in CF patients for IgA
anti-CAP (p < 0.05), although this was not necessarily
reflected in increased seropositivity (Fig. 2). Correlations
for IgG anti-CCP and IgG anti-CAP levels were found in
HC (ρ = 0.57, p < 0.001), patients with PD (ρ = 0.32, p <
0.001) and patients with BR (ρ = 0.47, p < 0.0001), and a
trend was observed in patients with CF (ρ = 0.28, p =
0.08). IgA anti-CCP and IgA anti-CAP levels were corre-
lated in HC (ρ = 0.41, p < 0.05), patients with PD (ρ =
0.39, p < 0.0001), patients with CF (ρ = 0.38, p < 0.05)
and patients with RA (ρ = 0.21, p < 0.05).
Rheumatoid factor
Compared with HC, IgM RF levels were increased in
patients with RA only (p < 0.0001), while IgA RF levels
were increased in BR (p < 0.0001), CF (p < 0.01) and
RA patients (p < 0.0001). IgM RF seropositivity was
7 %, 23 %, 7 % and 74 % in PD, BR, CF and RA patients
respectively, and 2.8 % in HC. Seropositivity for IgA RF
was 5.3 %, 24 %, 17 %, 50 % in PD, BR, CF and RA
patients respectively, and 2.8 % in HC (Fig. 3).
Anti-CarP antibodies and peptide specific reactivity
Compared with HC, IgG anti-CarP levels were increased
in patients with RA (p < 0.0001). Seropositivity for IgG
anti-CarP was observed in PD, BR and CF patients (3.5 %,
3.8 % and 7.3 %, respectively), but not in HC (Table 2).
The percentage of seropositive patients with RA (48 %)
was congruent with anti-CarP seropositivity in another
Dutch cohort of patients with RA (45 %) [41]. Compared
with that in HC, IgG reactivity against all investigated
citrullinated peptides was increased in patients with RA
Table 1 Patient characteristics
Patient group Rheumatoid arthritis Periodontitis Bronchiectasis Cystic fibrosis Healthy controls p value (vs. HC)
Subjects (n) 86 114 80 41 36
Age, yr, median (IQR) 57 (48–64) 50 (45–57) 65 (56–71) 28 (21–36) 26 (24–46) ***RA, PD and BR
Female (%) 56 59 63 49 60 n.s.
Current smoker (%) 60 42 2.5 0 14 **PD, *for BR and CF
Ever smoker (%) 17 36 44 0 8.3 **PD, ***BR
Never smoker (%) 22 22 54 100 78 ***PD, *BR, **CF
PISA (cm2), median (IQR) n.a. 14 (9.0–19) n.a. n.a. n.a.
%FEV1, median (IQR) n.a. n.a. 81 (60–97) 54 (36–80) n.a.
Exacerbations (n), median (IQR) n.a. n.a. 4 (3–6) 2 (1–3) n.a.
DAS28, median (IQR) 2.2 (1.7–2.8) n.a. n.a. n.a. n.a.
CRP (mg/L), median (IQR) 1.9 (1.0–6.0) 1.0 (0.6–2.4) 5 (2.0–13) 6.0 (4.0–14) 0.4 (0.3–1.5) ***RA, BR and CF
No periodontitis (%) 31 0 n.a. n.a. 100
Moderate periodontitis (%) 41 0 n.a. n.a. 0
Severe periodontitis (%) 28 100 n.a. n.a. 0




MTX + aTNFα (%) 3.5
MTX + SASP (%) 4.7
Other (%) 3.5
None (%) 3.5
aTNFα anti-TNFα inhibitors, CRP C-reactive protein, DAS28 Disease Activity Score 28 tender and swollen joint count, Exacerbations based on the number of
antibiotic courses 12 months before inclusion, %FEV1 percentage predicted forced expiratory volume, MTX methotrexate, n.a. not assessed, n.s. not significant,
PISA periodontal inflamed surface area, SASP sulfasalazine
*p < 0.05, **p < 0.01, ***p < 0.0001 (Kruskal–Wallis one-way analysis of variance with Dunn’s multiple-comparisons post-test or Fisher’s exact test with two-tailed
p value)
Fig. 1 Serum immunoglobulin G (IgG) (a) and IgA anti-cyclic citrullinated peptide (anti-CCP) (b) levels in healthy controls (HC) and in patients with
periodontitis (PD), bronchiectasis (BR), cystic fibrosis (CF) and rheumatoid arthritis (RA). Cutoff values are indicated: diagnostic cutoff (25 U/ml) and >2
SD above the mean of HC for IgG anti-CCP and >2 SD above the mean of HC for IgA anti-CCP. Seropositivity (%) is indicated for cutoff based on >2 SD
above the mean of HC. Bar indicates the median. **p < 0.01, ***p < 0.0001, Kruskal–Wallis one-way analysis of variance with Dunn’s multiple-
comparisons post-test compared with HC if overall p < 0.05
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Fig. 2 Serum immunoglobulin G (IgG) (a) and IgA anti-cyclic arginine peptide (anti-CAP) (b) levels in healthy controls (HC) and in patients with
periodontitis (PD), bronchiectasis (BR), cystic fibrosis (CF) and rheumatoid arthritis (RA). CAP represents the native counterpart of CCP. Cutoff values
are indicated: >2 SD above the mean of HC. Bar indicates the median. *p < 0.05, **p < 0.01, Kruskal–Wallis one-way analysis of variance with
Dunn’s multiple-comparisons post-test compared with HC if overall p < 0.05
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seropositivity against the various citrullinated peptides was
not increased in other patient groups studied (Table 2).
Compared with that in HC, IgA reactivity against citrulli-
nated fibrinogen-1 was increased in patients with RA (p <
0.01), as was seropositivity (19 %) (Table 2).
Compared with that of HC, IgA reactivity against na-
tive fibrinogen-2 (p < 0.0001) and vimentin (p < 0.01)
was increased in patients with CF. No differences in
seropositivity were observed for the various native pep-
tides between all groups for both immunoglobulin iso-
types (Table 2).Fig. 3 Serum immunoglobulin M rheumatoid factor (IgM RF) (a) and IgA R
(PD), bronchiectasis (BR), cystic fibrosis (CF) and rheumatoid arthritis (RA). C
Bar indicates the median. **p < 0.01, ***p < 0.0001, Kruskal–Wallis one-way
compared with HC if overall p < 0.05Regression analysis
Logistic regression analysis, adjusted for age, sex and
smoking (former and current versus never), revealed that
IgG anti-CCP seropositivity was more frequent in BR
(odds ratio [OR], 8.6; 95 % CI, 1.5–50; p < 0.05) and RA
(OR, 226; 95 % CI, 39–1309; p < 0.0001). The associ-
ation with PD was borderline significant (OR, 5.2; 95 %
CI, 0.99–27; p = 0.05). IgA anti-CCP seropositivity was
associated with CF (OR, 4.4; 95 % CI, 1.1–18; p < 0.05)
and RA (OR, 43; 95 % CI, 10–187; p < 0.0001). IgM RF
seropositivity was associated with RA (OR, 10; 95 % CI,
10–757; p < 0.0001), whereas the association with BRF levels (b) in healthy controls (HC) and in patients with periodontitis
utoff values are indicated: 10 IU/ml for IgM RF and 25 IU/ml for IgA RF.
analysis of variance with Dunn’s multiple-comparisons post-test
Table 2 Percentages of seropositivity for anti-carbamylated antibodies and various citrullinated peptides and their native arginine
counterparts according to cutoff levels of >2 SD above the mean of healthy controls
Patient group Healthy controls Periodontitis Bronchiectasis Cystic fibrosis Rheumatoid arthritis
Anti-CarP IgG (% pos.) 0 3.5 3.8 7.3 48
Peptides IgG (% pos.)
Cit. fibrinogen-1 2.8 0.9 1.3 0 55
Arg. fibrinogen-1 0 0.9 1.3 2.4 0
Cit. fibrinogen-2 0 4.4 2.5 0 71
Arg. fibrinogen-2 2.8 3.5 3.8 4.9 2.3
Cit. α-enolase 0 0.9 2.5 0 38
Arg. α-enolase 2.8 1.8 6.3 4.9 1.2
Cit. vimentin 0 1.8 0 0 48
Arg. vimentin 5.6 5.3 1.3 7.3 1.2
Peptide IgA (% pos.)
Cit. fibrinogen-1 0 0.9 0 0 8.1
Arg. fibrinogen-1 2.8 0.9 2.5 0 0
Cit. fibrinogen-2 2.8 2.6 0 0 19
Arg. fibrinogen-2 0 7.9 2.5 9.8 4.7
Cit. α-enolase 0 2.6 0 0 7.0
Arg. α-enolase 8.3 2.6 6.3 7.3 4.7
Cit. vimentin 0 0 0 0 4.7
Arg. vimentin 5.6 4.4 2.5 4.9 2.3
Arg. Arginine, Anti-CarP anti-carbamylated protein; Cit. citrulline, Ig immunoglobulin, % pos. percentage positive
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0.05). IgA RF seropositivity was associated with CF (OR,
10; 95 % CI, 1.1–97; p < 0.05) and RA (OR, 20; 95 % CI,
2.4–163; p < 0.01). Smoking was only of influence on the
association of IgA RF with RA (p < 0.01), as there were no
smokers among the patients with CF. Apart from that,
smoking, age and sex had no influence on the association
of the diseases with anti-CCP or RF seropositivity.
Association of disease activity with autoantibody status
Pulmonary function, measured as %FEV1, was significantly
worse in BR and CF patients seropositive for IgA RF (p <
0.01 and p < 0.05, respectively). Disease activity, as mea-
sured by the number of exacerbations 12 months before
inclusion based on the number of antibiotic courses, was
associated with seropositivity for IgA anti-CCP in patients
with CF (p < 0.01). Disease extent of PD, measured as
PISA, was negatively associated with anti-CarP seroposi-
tivity (p < 0.05). RA disease activity, as measured by
DAS28, was associated with seropositivity for IgG anti-
CCP (p < 0.05) and IgA RF (p < 0.05), whereas the associ-
ation with anti-CarP was borderline significant (p = 0.05).
Discussion
To our knowledge, this is the first study in which serum
IgA anti-CCP and anti-CarP levels have been assessed in
non-RA patients with inflammation of oral or lungmucosal tissues. Both IgG and IgA anti-CCP levels
were increased in patients with CF compared with HC,
and IgA anti-CCP seropositivity was associated with
presence of CF.
Besides one study reporting 1 of 45 adult patients with
CF seropositive for IgG anti-CCP [23], no data on anti-
CCP levels in patients with CF have been published. IgG
anti-CCP seropositivity was associated with presence of BR,
whereas the association with PD was borderline significant.
According to the diagnostic cutoff for IgG anti-CCP, similar
seropositivity (3.3 %) has been reported in a comparable BR
patient cohort [42], whereas seropositivity of up to 8 % has
been reported in patients with PD [43–45]. However, these
studies comprised PD patient groups of limited sample size
compared with our PD group. Our results for patients with
PD are better than those reported by de Pablo et al. [33],
who found, according to their diagnostic cutoff, 1 % IgG
anti-CCP seropositivity in patients with PD.
Both IgM and IgA RF were increased in patients with
CF compared with HC, and IgA RF seropositivity was as-
sociated with presence of CF. The former findings are in
accord with other reports in the literature [24]; however,
Koch et al. [23] found only slightly elevated RF in a cohort
of 65 adult and pediatric CF patients and concluded that
these laboratory findings were mostly nonspecific. IgM RF
was increased in patients with BR compared with HC, and
the association of IgM RF seropositivity with presence of
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BR (23 %) is in accord with a recent comparable study
[42]. The importance of RF and anti-CCP in BR and CF
patients is emphasized by the fact that pulmonary function
was significantly worse in BR and CF patients seropositive
for IgA RF, which has been reported for patients with CF
[46]. In addition, the number of exacerbations in patients
with CF was associated with IgA anti-CCP seropositivity.
Anti-CarP seropositivity was rather specific for RA. The
importance of anti-CarP was underlined by a correlation
with RA disease activity, in accordance with the findings
of Shi et al. [8]. Recently, next to citrullination, carbamyla-
tion has been hypothesized to play a role in the association
of PD and RA [30]. Serum anti-CarP levels were not in-
creased in patients with PD, although seropositivity in HC
was absent. The extent of periodontal disease was not as-
sociated with anti-CCP or RF seropositivity; nevertheless,
the unknown periodontal status of BR and CF patients re-
mains a limitation of our study. The extent of periodontal
disease was negatively associated with anti-CarP seroposi-
tivity, the implication of which is unclear.
Our HC should ideally be better age-matched, because
a trend toward increased amounts of serum IgM RF with
advancing age has been described [47], especially in ad-
vanced elderly people without RA (aged >78 years) [48].
However, the latter study found that only 1 of 300 ad-
vanced elderly subjects was IgG anti-CCP-seropositive
when the cutoff level was set at the 98th percentile of
blood donors aged 40–65 years (mean age, 50 years),
which represents ages of patients for whom immuno-
logical tests for RA are typically performed [48]. This
age range is comparable to that of our PD, BR and RA
patients. Together with the absence of significant influ-
ence of age in the logistic regression model, we assume
that RF and anti-CCP seropositivity is not much influ-
enced by age differences among patient groups. Regarding
anti-CarP, we cannot comment on the contribution of the
age factor in our patient groups, because its relationship
with age has not been tested in healthy populations.
Among the PD, BR and CF patients and HC, no differ-
ences were found in IgA or IgG seropositivity for the
citrullinated peptides of candidate autoantigens in RA
(e.g., citrullinated α-enolase). Increased IgG reactivity
against citrullinated α-enolase in patients with PD was re-
ported previously [33, 45]. Of note, these studies showed
increased reactivity against the native peptide of citrulli-
nated α-enolase as well. Therefore, the observed increased
levels of anti-citrullinated α-enolase were probably, at least
in part, not citrulline-specific. To rule out this possibility,
we assessed the difference in reactivity against the citrulli-
nated peptide and its native counterpart. Likewise, the
specific reactivity against the native forms of the peptides
was assessed. Break of tolerance toward native forms of
citrullinated autoantigens may lead to reactivity againstcitrullinated autoantigens via epitope spreading [33]. Brink
et al. [32] supported this hypothesis by reporting IgG sero-
positivity for various native peptides in a limited number
of pre-symptomatic patients with RA. The correlations
between anti-CCP and anti-CAP levels in our patient
groups suggest that at least part of the observed anti-CCP
reactivity is not citrulline-specific. A non-citrulline-
specific anti-CCP response has been reported in patients
with tuberculosis [49, 50]. In addition, in all our patient
groups, there was limited IgA and IgG seropositivity to-
ward one or more native peptides. Especially the patients
with CF showed an increased IgA response against CAP,
native fibrinogen-2 and vimentin peptides, but this not
reflected in increased seropositivity for these antigens.
Seropositivity for native antigens was also observed in HC
and might not be of clinical relevance. It remains unclear
whether reactivity toward citrullinated peptides can be
preceded by reactivity against their native forms, because
no longitudinal data of our study subjects were available.
P. gingivalis has been speculated to contribute to the
initiation of ACPA generation because of PPAD expres-
sion. No increased reactivity was found against citrulli-
nated α-enolase in patients with PD, the candidate RA
autoantigen that shows sequence similarity with P. gingi-
valis enolase [51]. In contrast to Lappin et al. [45], in
our study we found no differences in ACPA levels be-
tween patients with PD with or without subgingival P.
gingivalis (data not shown). Differences in study meth-
odology, including P. gingivalis detection, could have
contributed to this different study result.
Low serum anti-CCP levels have also been reported for
gastrointestinal mucosal inflammation [52, 53]. Because
RA-AAB are thought to be induced locally, serum levels
might not necessarily reflect local autoantibody produc-
tion. ACPA have been found in gingival crevicular fluid of
patients with PD [54] and in sputum of subjects at risk for
RA [22]. To our knowledge, local ACPA production in the
gastrointestinal tract has not yet been investigated.
Conclusions
Although overall levels were low, the presence of IgG and
IgA anti-CCP and IgM and IgA RF is independent of age,
sex and smoking associated with lung mucosal inflamma-
tion (BR and CF) and may be associated with oral mucosal
inflammation (PD). RA-AAB in the peripheral blood in
the presence of mucosal inflammation, albeit not accord-
ing to the diagnostic cutoff level, supports the hypothesis
that formation of these autoantibodies may be induced at
inflamed mucosal surfaces. To further determine whether
mucosal inflammation functions as a site for induction of
RA-AAB and precedes RA, longitudinal studies are neces-
sary in which RA-AAB of specifically the IgA isotype
should be assessed in inflamed mucosal tissues and/or in
their inflammatory exudates.
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